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Background: Two randomized trials have shown similar mid-term outcomes for survival and quality of life after
endovascular and conventional open repair of abdominal aortic aneurysms (AAA). With reduced hospital and intensive
care stay, endovascular repair has been hypothesized to be more efficient than open repair. The Dutch Randomized
Endovascular Aneurysm Management (DREAM) trial was undertaken to assess the balance of costs and effects of
endovascular vs open aneurysm repair.
Methods: We conducted a multicenter, randomized trial comparing endovascular repair with open repair in 351 patients
with an AAA and studied costs, cost-effectiveness, and clinical outcome 1 year after surgery. In addition to clinical
outcome, costs and quality of life were recorded up to 1 year in 170 patients in the endovascular repair group and in 170
in the open repair group. Incremental cost-effectiveness ratios were estimated for cost per life-year, event-free life-year,
and quality adjusted life-year (QALY) gained. Uncertainty regarding these outcomes was assessed using bootstrapping.
Results: Patients in the endovascular repair group experienced 0.72 QALY vs 0.73 in the open repair group (absolute
difference, 0.01; 95% confidence interval [CI], 0.038 to 0.058). Endovascular repair was associated with additional
€4293 direct costs (€18,179 vs €13.886; 95% CI, €2,770 to €5,830). Most of the bootstrap estimates indicated that
endovascular repair resulted in slightly longer overall and event-free survival associated with respective incremental
cost-effectiveness ratios of €76,100 and €171,500 per year gained. Open repair appeared the dominant strategy in costs
per QALY.
Conclusion: Presently, routine use of endovascular repair in patients also eligible for open repair does not result in a QALY
gain at 1 year postoperatively, provides only a marginal overall survival benefit, and is associated with a substantial, if not
prohibitive, increase in costs. ( J Vasc Surg 2007;46:883-90.)Endovascular repair of abdominal aortic aneurysms
(AAA) has been demonstrated to reduce death and com-
plication rates in the first month after the procedure com-
pared with open repair.1,2 Subsequent longer term analysis
of these randomized trials showed a sustained benefit in
terms of aneurysm related mortality up to 4 years, but the
difference in overall survival did not persist beyond the first
2 postoperative years.3,4 Consequently, only a very limited
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Clearly, incorporating other factors such as economics and
health-related quality of life (HRQOL) becomes impera-
tive to assess and compare both treatment options.
Several studies, including the two randomized trials,
have documented reduced hospital stay and intensive care
unit (ICU) stay after endovascular repair compared with
open repair.1,2,5-7 These reductions, together with im-
provement of patient recovery time, might result in re-
duced immediate costs of AAA repair. However, this initial
cost advantage may be offset by life-long and frequent
follow-up imaging as recommended after endovascular re-
pair.8 We have shown that the costs associated with the
mandatory long-term surveillance are considerable.9
In addition to cost advantages, other reports have sug-
gested that the minimally invasive nature of endovascular
repair may be associated with better quality of life after the
operation.10-12 We have previously addressed this issue by
specifically looking at HRQOL in patients randomized to
endovascular repair or open repair.13 Only in the early post-
operative period could we demonstrate a minimal QOL ad-
vantage of endovascular repair vs open repair. In the second
half of the first year, however, better QOL was actually re-
ported after open repair than after endovascular repair. This
might further limit the possible advantage of endovascular
repair compared with open repair.
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paring costs of endovascular and open aneurysm repair have
been published, and results were conflicting.14-18 The larg-
est trial thus far reported no advantage of endovascular
repair in terms of HRQOL and costs.4 A full economic
evaluation using trial based data is lacking, however. This
would appear to hamper a truly considered policy decision
on the issue. We anticipated that health economics might
be required to finalize the discussion and conducted a
comprehensive economic evaluation in parallel to our mul-
ticenter randomized trial, the Dutch Randomized Endo-
vascular Aneurysm Management (DREAM) trial. Thus a
head-to-head comparison of the balance between costs and
effects after elective endovascular and open AAA repair was
obtained.
METHODS
Study design and patients. A detailed description of
the design and methods of the DREAM trial has been
presented elsewhere.19 In brief, patients diagnosed with an
AAA of 5 cm in diameter who were considered suitable
for both techniques were randomly assigned to endovascu-
lar repair or open repair, after giving written informed
consent. The study excluded patients requiring emergency
AAA repair and patients with inflammatory aneurysms,
anatomic variations, connective tissue disease, previous or-
gan transplantation, and a life expectancy of 2 years. The
study was performed according to the principles of the
Declaration of Helsinki. The Institutional Review Boards
of all participating hospitals approved the protocol. The
present analyses are limited to patients with complete
1-year data on costs and effects by fall 2005.
End points. Complications were classified and graded
according to the reporting standards of the Ad Hoc Com-
mittee for Standardized Reporting Practices in Vascular
Surgery of The Society for Vascular Surgery/International
Society for Cardiovascular Surgery.20,21 A committee
blinded to the treatment allocation evaluated the clinical
outcomes. Three severity grades—mild, moderate, and
severe—were distinguished. Only severe events were con-
sidered for the present analyses.
Quality of life. HRQOL was assessed with the Dutch
language version of the EuroQol 5 Dimensions question-
naire (EQ-5D) using the summary score based on the tariffs
by Dolan.22 The EQ-5D questionnaire is a multiattribute
instrument reflecting the societal preferences and values for
the five domains discerned and their mutual interdepen-
dence. Value judgments have been derived previously, in-
dependent of potential (economic) cost consequences for
current patients. At different points in time, utility scores
were obtained by means of EQ-5D. The EQ-5D results in
a single numeric score that represents the societal valuation
of the actual health status. A value of 1 represents optimal
health, and 0 represents death.
Questionnaires were sent to patients at baseline (upon
randomization), at 3 and 6 weeks, and at 3, 6, and 12
months postoperatively. Using linear interpolation for the
periods between measurements, we calculated the quality-adjusted survival time in terms of quality-adjusted life-years
(QALY) by determining the individual area under the
curve. These results were previously reported.13 For the
present analyses, the results of the remaining patients that
completed their 1-year follow-up were added. We used
simple imputation based on clinical outcome to obtain a
“complete” data set. Baseline and other (outcome) charac-
teristics of the patients with missing data were no different
from those with complete data.
Costs. Medical costs associated with treatment and
follow-up until 1 year after inclusion were assessed in
Euros. Costs per patient were calculated by multiplying
individual resource use with unit costs. The volume of the
resource use during admission and follow-up (out-patient
visits) was recorded in the case record forms and completed
by means of patient diaries. The latter were specifically
designed to capture additional resource use such as consul-
tations of a physiotherapist or family physicians, home care,
medication used, and other admissions, such as for rehabil-
itation. Additional examinations specifically performed for
study purposes and not serving any clinical purpose, such as
additional computed tomography angiography follow-up
in the open repair group, were not included in the analysis.
Where unavailable from existing sources, unit costs were
determined in two academic and two peripheral hospitals.
Notably, the costs of the devices were based on the
actual purchasing prices (inclusive of value added taxes and
shipping). Personnel costs comprised all individuals in-
volved, inclusive of specialists and operating room staff. A
weightedmean of costs per itemwas calculated by using the
ratio of the patients treated in academic and peripheral
settings.
We based our estimates of average costs per hospital day
(ICU and ward) on a study previously performed in the
Netherlands.23 Costs of outpatient visits, visits to family
physicians, and home care were calculated from unit costs
reported by the Dutch Costing Manual issued by the
National Health Insurance Council.24 Costs of medication
were estimated using theDutch Formulary (Pharmacother-
apeutic Compass 2003) and included the pharmacist’s
charges. Costs of rarely performed interventions were based
on national tariffs (College Tarieven Gezondheidszorg
(CTG), http://www.ctg-zaio.nl). Where necessary, unit
costs were adjusted to 2003 values according to National
Health Service Costs Index issued by the National Bureau
for Statistics Netherlands.
We also assessed costs due to losses in productivity
associated with sick leave and travel as well as other private
costs incurred by patients and their families. Time costs
were valued using the friction cost method.25 The Health
and Labour Questionnaire26 was used to assess actual sick
leave.
Cost-effectiveness. For the economic evaluation, the
estimates of QALY were chosen as the primary measure of
effect. The balance between costs and effects of endovascu-
lar repair compared with open repair was expressed in terms
of incremental costs per QALY gained using a societal
perspective. The incremental cost-effectiveness ratio was
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a 1-year period by the difference in QALYs. The incremental
costs per year without severe complications and per life-year
gained were estimated as secondary outcome measures.
The time horizon considered for the current analyses
was 1 year. Accordingly, the time preference for any of the
outcomes was considered negligible, thus obviating dis-
counting of costs and effects.
Statistical analysis. Patients were classified according
to the original treatment allocated for all analyses (as ran-
domized). Mortality and complication rates at 1 year were
compared between the two trial arms using the 2 test.
Because the distribution of costs across individuals
tends to be skewed, calculating conventional confidence
intervals (CI) is hampered because these are based on the
assumption of normal distribution. Furthermore, the con-
cept of a 95% CI pertaining to a ratio of incremental costs
and effects is problematic as such. A negative incremental
cost-effectiveness ratio may imply a negative cost difference
(cost savings) and positive health effects, or a positive cost
difference (extra costs) and negative health effects. The first
would obviously be an outcome leading to immediate imple-
mentation, whereas the latter would call for immediate halt to
the experimentalmethod. Likewise, positive incremental cost-
effectiveness ratiosmay be attained by positive cost differences
and positive health effects, or negative cost differences and
negative health effects. These situations might also have quite
different implications; therefore, a single point estimate of
average incremental cost-effectiveness with pertaining 95%CI
a priori is a useless concept.
Accordingly, it has become customary in health eco-
nomics to depict the joint distributions of incremental costs
and effects with their pertaining uncertainty in a “cost-
effectiveness plane,” where incremental costs are on the
y-axis and incremental effects are on the x-axis. To evaluate
the joint uncertainty in trial data while maintaining the
underlying correlation between costs and effects, a boot-
strap procedure may be applied.27 Patients are randomly
drawn from the original trial data set, without being ex-
cluded for subsequent sampling, until the original number
of participants is reached. This process is typically repeated
several 1000 times, and for each trial replicate, the incre-
mental costs and effects are calculated, to be depicted in the
cost-effectiveness plane. Then, nonparametric 95% CI for
the incremental costs can be calculated, and the density
distribution of the incremental cost-effectiveness ratio ap-
pears in the cost-effectiveness plane.
Thus, our analysis presents costs and health outcomes
as the means per patient inclusive of 95% CIs. From the
original data set, 10,000 bootstrap replicates were drawn
and the incremental costs for each replicate were plotted
against the incremental effects representing the uncertainty
surrounding the incremental cost-effectiveness ratio.
RESULTS
Characteristics of the patients and treatment
assignments. Details of the clinical study results were pre-
viously reported.1,19 Briefly, between November 2000 andDecember 2003, 351 patients were randomly assigned to
endovascular repair or open repair. Six patients did not
undergo aneurysm repair after randomization: four de-
clined treatment (1 assigned to endovascular repair and 3 to
open repair), and one patient in each group died. Five
patients were lost to follow-up in the first year. This re-
sulted in a study group of 340 patients, with 170 open
repairs and 170 endovascular repairs. Five crossovers oc-
curred: one patient assigned to endovascular repair had
open repair, and four patients assigned to open repair had
endovascular repair.
Baseline characteristics of patients and aneurysms are
given in Table I. The two groups had similar demographic
characteristics, comorbid conditions, cardiovascular risk
profile, American Society of Anesthesiologists classifica-
tions, and aneurysm characteristics.
End points. In the first postoperative year, one or
more severe complications occurred in 33 patients in the
endovascular repair group and in 37 in the open repair
group (P .6). Death (all causes) occurred in 10 patients in
the endovascular repair group and 12 in the open repair
group (P  .7). Aneurysm related events occurred in two
patients in the endovascular repair group and nine in the
open repair group (P  .03). Detailed results were previ-
ously reported.3
Quality of life. A marginal and nonsignificant benefit
Table I. Baseline characteristics*
Characteristic*
OR
(n  170)
EVAR
(n  170)
Age, y 69.4  6.8 70.7  6.6
Male sex 154 (91) 158 (93)
SVS/ISCVS risk-factor score, %†
Diabetes mellitus 8.8 10.0
Tobacco use 55.3 64.7
Hypertension 54.7 58.2
Hyperlipidemia 53.7 47.3
Carotid disease 15.3 13.5
Cardiac disease 46.5 41.2
Renal disease 7.6 7.6
Pulmonary disease 18.2 27.1
Total† 4.5  2.5 4.4  2.5
FEV1, L/s 2.6  0.7 2.5  0.7
Body mass index, kg/m2 26.5  4.0 26.3  3.4
ASA class
I—healthy status 41 (24) 37 (22)
II—mild systemic disease 105 (62) 119 (70)
III—severe systemic disease 24 (14) 14 (8)
Maximum AAA diameter, mm 60.0  8.5 60.6  9.0
OR, Open repair; EVAR, endovascular repair; SVS/ISCS, Society for Vas-
cular Surgery/International Society for Cardiovascular Surgery; FEV1,
forced expiratory volume in 1 second; ASA, American Society of Anesthe-
siologists; AAA, Abdominal aortic aneurysm.
*Continuous data are presented as means  SD, and categoric data as
number (%) and percentages (because of rounding not all percentages total
100).
†Mild, moderate, or severe risk-factor SVS/ISCS score ranges for each of
eight domains from 0 (no risk factors) to 3 (severe risk factors).20 Total
scores can range from 0 to 24, with higher scores indicating more risk
factors.of open repair compared with endovascular repair was
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for the economic evaluation 1 year after randomization.
Patients who underwent endovascular repair experienced
0.72 QALYs (95% CI, 0.29 to 1.14), and patients that
underwent open repair experienced 0.73 QALYs (95% CI,
0.27 to 1.19); that is, a nonsignificant 0.01 QALY loss
(95% CI,0.038 to 0.058) was observed after endovascu-
lar repair (Fig 1).
Costs. The estimates of the main unit costs are pre-
sented in Table II. Actual averages of total costs per patient
according to treatment at 1 year are presented in Table III.
The estimated difference, as estimated with bootstrap rep-
licates of the trial, amounted to €4300 per patient (95% CI,
€2770 to €5830) in favor of open repair (€13,886 for open
repair vs €18,179 for endovascular repair). The greater part
of the cost difference was attributable to the costs of the
endoprosthesis, which was only partly compensated for by
savings in admission costs ensuing from shorter lengths of
stay in the ICU and on the regular ward. The costs of
surveillance of the endovascular repair group also contrib-
uted to the difference. Only 24 patients reported paid
employment, resulting in only minimal costs associated
with loss in productivity (Table III). Focusing on these 24
patients, the mean costs due to sick leave were €3820 in 11
patients (95% CI €1509 to €6131) in the endovascular
repair group and €4,662 for 13 patients (95% CI, €2511 to
€6812) in the open repair group.
Cost-effectiveness. In terms of QALYs, open repair
appeared to be the dominant strategy; that is, costs were
lower and better results were observed, albeit marginal and
nonsignificant. The incremental cost-effectiveness ratio in
terms of costs per year without severe complications was
€76,100 and was €171,500 for costs per life-year gained.
Results of the bootstrapping are depicted in cost-
effectiveness planes in Fig 2. The QALYs gained panel
(Fig 2, A) shows that 65% of replicates fall into the left
Fig 1. Utility score over time in the first postoperative year after
endovascular repair (gray line) and open repair (dashed line) with
95% confidence intervals. Area under the curve equals quality-
adjusted life years.upper quadrant, indicating that we can be 65% certain thatopen repair yields a marginally better outcome in terms of
QALYs at 1 year. Note that all replicates lie above the
x-axis, indicating that with 100% certainty endovascular
repair is more costly. The oblique line indicates a (rather
arbitrary) societal willingness to pay a threshold of €25,000
per QALY. All replicates lie above this threshold, indicating
that with 100% certainty open repair can be considered the
preferred strategy at a societal €25,000 per QALY willing-
ness to pay threshold. Note that even if a threshold of
€50,000 per QALY gained would be considered accept-
able, still99% of estimates would lie above this threshold.
Fig 2, B (event-free years gained) and Fig 2, C (life-years
gained) show that, respectively, 95% and 85% of the repli-
cates fell into in the right upper quadrant. This indicates
that with high certainty that endovascular repair had favor-
able health outcomes but against higher costs.
DISCUSSION
Sound evidence shows that early survival after endovas-
cular repair is better; however, within a few years, the frail
survivors of endovascular repair seemed to have died just
the same, leaving on average an overall benefit of only just
11 days. Because this almost negligible survival advantage
comes at considerable financial costs, it is clear that major
shifts in endograft pricing and follow-up protocols are
mandatory before health care payers would consider reim-
bursement of endovascular repair money well-spent. More-
over, in terms of costs per QALY gained, there was an
indication of open repair being the dominant strategy. The
costs after endovascular repair were higher, and in terms of
QALYs, a net loss was observed.
Similar to our findings in terms of utility scores beyond
the sixth postoperative month, the EndoVascular Aneu-
rysm Repair-1 (EVAR-1) trial showed a nonsignificant
difference in favor of open repair.4 Forbes et al28 performed
Table II. Main unit costs based on cost study
Variable Unit costs (€)
Preoperative
Workup, inclusive examinations and visits 493
Intraoperative
Operation room per hour 15
Anesthesia, excluding personnel
OR: university hospital 436
OR: general hospital 316
EVAR: university hospital 206
EVAR: general hospital 75
Inpatient hospital days*
Ward: university hospital 330
Ward: general hospital 240
Medium care unit 735
Intensive care unit 1140
Investigations
Angiography 662
CT angiography 183
Duplex scanning 84
OR, Open repair; EVAR, endovascular repair; CT, computed tomography.
*From Oostenbrink, et al.23a cost-effectiveness analysis and reported comparable re-
lute d
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patients (7 endovascular repairs, 31 open repairs) electively
treated for an AAA. Other studies using a Markov-model
suggested that endovascular repair was cost-effective com-
pared with open repair.17,18
These results are in marked contrast with our findings
showing that the incremental costs associated with endo-
vascular repair are considerably higher compared with open
repair in the first year after surgery. Among the plausible
explanations for these contradicting findings are that Patel
et al17 used a combined and lasting mortality and severe
morbidity rate of 1.1% for endovascular repair vs 9.1% for
open repair, which was later shown to be too optimistic for
endovascular repair. Even at that time, it was concluded
that the cost-effectiveness of endovascular repair would
critically depend on its potential to reduce morbidity and
mortality rates.
In this respect, the two randomized trials (EVAR-1 and
DREAM) provided sound evidence of a short-term benefit
of endovascular repair vs open repair for operative mortality
and complications.1,2 Both trials also reported a significant
reduction in hospital length of stay, ICU use, systemic
complications, and use of other resources such as produc-
tivity losses due to sick leave. As a result, endovascular
repair was expected to lead to significant savings in hospital
and other costs; however, the use of actual cost data and
accounting for longer-term results challenged this expecta-
tion.
The savings realized seem to be largely offset by the
costs of the endoprostheses, which are eight to ten times
more expensive than conventional prostheses. Sternberg
and Money14 found that the costs of an endoprosthesis
Table III. Average costs per patient per treatment group
Variable Costs
Direct costs in hospital 11,9
Operation 56
Use of operating room 5
Operating room personnel, inclusive of specialists 42
Conventional prosthesis 4
Endovascular prosthesis 1
Other materials 1
Admission (ward  ICU) 60
Additional costs* 2
Direct costs during 1-year follow-up 16
Standard follow-up 2
Complications 2
Sick leave 3
Outpatient health care† 7
Total‡ 13,6
Estimate total direct costs using bootstrap‡ 13,8
OR, Open repair; EVAR, endovascular repair; CI, confidence interval; ICU
*Investigations, medications, etc.
†Open repair, n  149; EVAR, n  156.
‡The actual trial-based absolute difference in costs is almost €5000. An accu
10,000 bootstrap replications of the trial. The resulting estimate of the absoaccounted for 52% of the total cost of endovascular repair.Likewise, in the study by Berman et al,15 70% of the costs of
endovascular repair were attributed to the endoprosthesis,
whereas in the open repair group 75% of the costs were
accounted for by hospital care outside the operating room.
A drawback of these two studies, and also other studies
on costs of endovascular repair and open repair, is that none
had a randomized design. This may have introduced selec-
tion bias, especially because endovascular repair was initially
intended for use in patients unfit for open repair. Neverthe-
less, the data of the present randomized trial show similar
results for initial intervention related costs, thus confirming
that the costs of the devices, apart from the cost of long-
term surveillance and possible complications, represent a
major part of the cost difference.
With regard to additional costs, another flaw of most
available economic studies is that they focused on in-
hospital costs only.16,28 A comprehensive economic analy-
sis should also include the costs of preoperative and post-
operative radiologic studies, the costs of preoperative and
secondary interventions, the costs of the procedure itself,
and finally the costs associated with regular follow-up. It is
well known that endovascular repair sometimes results in
specific complications, including endoleak and endograft
migration, kinking, and rupture.29-31 These complications
are rare or impossible after open repair.31
Despite decreased endograft-specific complication rates
with newer endovascular devices, life-long follow-up is still
considered mandatory after endovascular repair. For cen-
ters that have also implemented an elaborate long-term
follow-up protocol for open repair patients, the cost disad-
vantage of endovascular repair would be somewhat smaller.
However, because the current analyses focus on short-term
e first postoperative year
R (n  170) EVAR (n  170)
95% CI Cost (€) 95% CI
10,674-13,277 14,915 14,283-15,546
5416-5928 12,679 12,292-13,066
533-547 308 293-323
4093-4420 3775 3579-3970
477-500 9 0-19
2-385 7857 7572-8143
131-258 730 635-824
4828-7195 2136 1705-2567
108-475 100 44-155
1334-1969 3618 3301-4160
249-283 829 807-850
265-317 1320 971-1669
120-593 247 56-438
494-964 1295 983-1607
12,297-14,957 18,595 17,835-19,335
18,179
sive care unit.
timate of the absolute difference and pertaining 95% CI was obtained using
ifference was €4,393 (95% CI, €2,770 to 5,830: €13,886 versus €18,179).in th
O
(€)
75
72
40
56
88
93
95
11
91
51
66
91
56
29
27
86
, inten
rate esoutcomes, the impact of accounting for routine follow-up
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accumulating costs of follow-up, costs associated with re-
interventions occurring at a rate as high as 10% per annum
after endovascular repair should be anticipated.32 It would
Fig 2. Cost-effectiveness planes for (A) quality-adjusted life
years, (B) event-free years gained, and (C) life-years gained for
costs of endovascular repair (ER) and open repair (OR). The
cost-effectiveness plane consists of four quadrants. A dot to the
right of the y-axis means that ER yields a better outcome, whereas
a dot on the left side means the OR yields a better outcome.
Likewise, a dot above the x-axis means that the costs of ER are
higher, whereas a dot below the x-axis implies that OR is more
expensive. The lower right and upper left quadrant would indicate
that both costs and effects are favorable (dominant) for ER and
OR, respectively. The percentages represent the proportion of
bootstrap replication in which the clinical outcome is favorable for
open repair. A, The oblique line indicates a societal willingness to
pay a threshold of €25,000 per quality-adjusted life year.appear that a less intensive follow-up protocol or one usingless costly diagnostic techniques is not justified before the
currently available or next generation devices are proven to
require fewer secondary interventions or to lead to reduced
long-term complication rates.33 In the future, this could
overcome part of the cost disadvantage of endovascular
repair; however, our economic evaluation suggests that
only a substantial drop in the price of the devices could
really tilt the balance.
A possible limitation of our study may be the restriction
to 1-year data. We would like to stress, however, that the
two randomized trials showed about 13% reinterventions at
2 years and 20% at 4 years after endovascular repair.3,4
Similarly, Laheij et al32 showed that the reintervention rate
does not decrease up to 4 years after endovascular repair in
a large observational study using European Collaborators
on Stent-Graft Techniques for AAA and Thoracic Aortic
Aneurysm and Dissection Repair (EUROSTAR) data. As a
result, we maintain that the present 1-year analysis, if
anything, yields an underestimation of the cost advantage
of open repair.Moreover, the limited initial benefit in terms
of survival time may ultimately vanish altogether because of
longer-term complications occurring. Clearly, long-term
cost-effectiveness will be driven by the need for long-term
surveillance, reinterventions with possible complications,
and even occasional aneurysm rupture.
Future generations of less costly and more effective and
reliable endografts may render the present analysis obso-
lete. We claim, however, that until sound evidence is pre-
sented that indeed devices have improved and reinterven-
tion rates have dropped considerably, meticulous follow-up
remains required. Even a slightly higher reintervention rate
after endovascular repair will retain the cost advantages of
open repair.
It is well known that item costs may differ across
national borders. In fact, the price paid in the United States
for a similar health care service may be up to twice that paid
in a typical Western European setting. This obviously has
implications for the incremental cost-effectiveness ratio. In
this case, the incremental cost difference is likely to increase
because costs in both arms of the trial would increase more
or less proportionally. The incremental effects, however,
likely would remain similar. Accordingly, the ratio of incre-
mental costs and effects as calculated for the Netherlands
might be an underestimate of that attained in a United
States setting. On the other hand, if in alternative settings
postoperative monitoring routines or long-term follow-up
schemes after endovascular repair would be less strict than
currently used in the Dutch setting, the incremental cost-
effectiveness might become somewhat less unfavorable.
We note again that the present analyses derive from
short-term data, and that therefore long-term follow-up
protocols make up only aminute part of the overall costs. In
the long run, these savings might result in an incremental
cost-effectiveness ratio somewhat less unfavorable for en-
dovascular repair, yet only if this would not be counterbal-
anced by an increased complication rate.
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The results of the present economic and cost-effectiveness
analyses demonstrate that a policy in which endovascular
repair is offered routinely to all eligible patients is associated
with considerable financial costs.3 As long as the risk of
death in the first year after endovascular repair cannot be
predicted more accurately or prevented by more aggressive
risk-factor management, the extra costs incurred may not
be justified by the benefit of general implementation of
endovascular repair.
Whether endovascular repair will become cost-effective
in the near future remains to be seen. Long-term data from
the randomized trials may shed new light on the issue. We
believe that only if quality of life, complication rates, and
survival after endovascular repair were to improve and the
costs of the devices would come down considerably, the
cost-effectiveness might change in favor of endovascular
repair.
Finally, routine use of endovascular repair in patients
also eligible for open repair does not result in QALY-gain at
1 year postoperatively and provides only a marginal overall
survival benefit while it is associated with a substantial if not
prohibitive increase in costs.
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